Anxiety Disorders And Depression Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Anxiety Disorders and Depression Treatment Market Report Segments the Industry Into by Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin–norepinephrine Reuptake Inhibitors (SNRIs) and More), by Indication (Major Depressive Disorder and More), by Therapy (Pharmacotherapy, Psychotherapy and More) and Geography (North America and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Anxiety Disorders And Depression Treatment Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Global Anxiety Disorders And Depression Treatment Market with other markets in Healthcare Industry

Global Anxiety Disorders And Depression Treatment Market Analysis by Mordor Intelligence

The global Anxiety disorder and depression treatment market stood at USD 22.65 billion in 2025 and is on track to reach USD 29.36 billion by 2030, progressing at a 5.32% CAGR. Growth is propelled by accelerating mental-health awareness, recent U.S. FDA rules that open over-the-counter (OTC)[1]Source: U.S. Food and Drug Administration, “Nonprescription Drug Product Additional Condition for Nonprescription Use,” fda.gov pathways for select SSRIs, and landmark approvals covering digital therapeutics and psychedelic-assisted therapies. AI-driven adherence platforms, rising adoption among younger demographics, and geriatric demand for safer formulations further support volume expansion. Meanwhile, rapid-acting NMDA antagonists and neuroplastogens challenge the dominance of monoamine-based drugs, while value-based pricing and mental-health parity rules reshape revenue models in key markets.

Report Key Takeways

By drug class, selective serotonin reuptake inhibitors led with 41.45% of the Anxiety disorder and depression treatment market share in 2024; atypical antipsychotics are forecast to advance at a 6.92% CAGR through 2030.
By indication, major depressive disorder accounted for 38.61% of the Anxiety disorder and depression treatment market size in 2024, while PTSD treatments post the highest 7.12% CAGR to 2030.
By therapy type, pharmacotherapy captured 69.53% revenue in 2024; digital therapeutics record the fastest 6.35% CAGR out to 2030.
By end user, hospitals & clinics controlled 52.45% revenue in 2024; homecare settings grow quickest at 7.16% CAGR through 2030.
By region, North America commanded 37.56% revenue in 2024; Asia-Pacific is projected to rise at an 8.02% CAGR.

Segment Analysis

By Drug Class: SSRIs Hold Ground While Novel Pathways Accelerate

SSRIs controlled 41.45% revenue in 2024, underpinning the Anxiety disorder and depression treatment market with extensive safety records. Atypical antipsychotics, however, climb at a 6.92% CAGR as adjunctive options in major depression. Expansion stems from lumateperone’s broader label prospects and brexpiprazole’s PTSD nod. Meanwhile, 5-HT1A agonists, glutamate modulators, and psychedelics populate the “others” bucket that investors view as white-space categories capable of altering first-line prescribing.


Competition intensifies as agents that avoid weight gain, sexual dysfunction, or sedation draw preference among working-age users. Manufacturers respond with precision-dose kits and co-packaged digital-support apps that track adherence in real time and flag side-effect profiles for clinician review. Benzodiazepine utilization contracts as payers restrict long-term scripts, opening space for non-sedating anxiolytics and GABA-positive allosteric modulators with safer abuse profiles.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Indication: Depression Still Dominates but PTSD Surges

Major depressive disorder generated 38.61% of 2024 revenue, reinforcing the Anxiety disorder and depression treatment market. PTSD, however, expands fastest at 7.12% CAGR, aided by FDA’s first approval of brexpiprazole plus sertraline and renewed interest in MDMA-assisted therapy despite Lykos’s recent setback.

Growing recognition of trauma across civilian life and veterans’ health policies widen the patient pool. Expanded diagnostic criteria for generalized anxiety disorder and social anxiety also unlock incremental volume, while obsessive-compulsive disorder remains underserved, thereby attracting pipeline focus on glutamatergic compounds and nasal sprays that promise rapid relief.

By Therapy Type: Digital Pairings Shift the Standard of Care

Pharmacotherapy still makes up 69.53% of 2024 spend, yet software-based adjuncts claim mindshare and regulatory legitimacy. Rejoyn’s 2024 FDA greenlight as the first Rx digital therapeutic positions app-pill bundles as future baseline care.

Digital tools extend dose-titration analytics, deliver cognitive training, and generate real-world evidence that secures payer acceptance. Device-driven neuromodulation—rTMS, tDCS, and implanted vagus stimulators—gains traction for refractory patients, while psychotherapy maintains steady relevance via hybrid telehealth models.

Global Anxiety Disorders and Depression Treatment Market: Market Share by Therapy Type
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Homecare Rises on Telehealth Adoption

Hospitals and clinics delivered 52.45% sales in 2024, although home settings are growing quickest at 7.16% CAGR. Telepsychiatry, remote vital-sign monitoring, and AI-generated adherence nudges underpin decentralized regimens. Employers embed mental-health benefits to moderate productivity loss, broadening scripts beyond clinical encounters and adding another distribution node for pharmaceutical partners.

Geography Analysis

North America retained leadership with 37.56% revenue in 2024, underpinned by robust insurance coverage, rapid uptake of new modalities, and favorable FDA policies. Breakthrough designations for psilocybin analogs and the OTC switch pathway illustrate regulatory flexibility that accelerates launch cycles. U.S. parity laws expand access but compress margins, compelling firms to defend value through outcomes contracts.

Asia-Pacific is set to be the growth engine with an 8.02% CAGR out to 2030. China’s NMPA approval of Ruoxinlin, a triple monoamine reuptake inhibitor, exemplifies regulatory modernization. Urbanization, social-media campaigns, and employer-led wellness programs reduce stigma, while price-sensitive segments favor generics. Japan, South Korea, and Australia spearhead digital-therapeutic adoption, whereas India’s large underserved population drives volume for low-cost SSRIs.

Europe posts steady mid-single-digit gains as EMA’s revised antidepressant guideline promotes personalized endpoints and cross-border trial efficiencies. Universal coverage across Germany, France, and the Nordics sustains demand for innovative products once cost-utility criteria are satisfied. South America and the Middle East & Africa remain nascent but promising as telehealth infrastructure spreads and government stigma-reduction campaigns take hold.

Global Anxiety Disorders and Depression Treatment Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The Anxiety disorder and depression treatment market features moderate concentration. Big Pharma—Eli Lilly, Pfizer, Johnson & Johnson—leverages broad portfolios, but biotech challengers capture headlines with rapid-acting or psychedelic approaches. J&J’s USD 14.6 billion buyout of Intra-Cellular Therapies secures lumateperone, signaling a readiness to pay premium for novel MoAs. AbbVie’s multi-deal spree with Gilgamesh and Gedeon Richter underscores the race to own neuroplastogen and bipolar-focused assets.

Strategic collaborations pair pharma scale with digital-health agility; Otsuka’s alliance with Click Therapeutics fast-tracked Rejoyn, creating a template for combined pill-app submissions. Manufacturers also target treatment-resistant niches, coupling ketamine or dextromethorphan with SSRIs to accelerate onset. Generic houses consolidate to hold volume share as branded patents lapse, while API shortages and inflationary pressure push contract prices upward, benefitting integrated suppliers.

Marketing strategies pivot to patient-reported outcome storytelling and hybrid care pathways that highlight reduced total-cost-of-care versus simple symptom relief. Investment in real-world data platforms expands as payers demand longitudinal evidence of functional improvement.

Global Anxiety Disorders And Depression Treatment Industry Leaders

  1. Pfizer Inc,

  2. GlaxoSmithKline

  3. Merck & Co. Inc

  4. Eli Lily & Co

  5. Johnson & Johnson

  6. *Disclaimer: Major Players sorted in no particular order
Anxiety Disorders and Depression Treatment Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • June 2025: Johnson & Johnson closed its USD 14.6 billion purchase of Intra-Cellular Therapies, adding lumateperone to its pipeline for adjunctive MDD treatment.
  • May 2025: Supernus Pharmaceuticals moved to acquire Sage Therapeutics for up to USD 795 million, boosting its CNS franchise.

Table of Contents for Global Anxiety Disorders And Depression Treatment Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising prevalence of anxiety & depression
    • 4.2.2 Growing geriatric population prone to mental disorders
    • 4.2.3 Pipeline approvals of novel antidepressant & anxiolytic agents
    • 4.2.4 Increased awareness & stigma reduction toward mental health
    • 4.2.5 OTC switch momentum for selected SSRIs (under-the-radar)
    • 4.2.6 AI-enabled digital therapeutics boosting adherence (under-the-radar)
  • 4.3 Market Restraints
    • 4.3.1 Patent expirations & generic erosion of blockbusters
    • 4.3.2 Adverse effects limiting long-term adherence
    • 4.3.3 Psychedelic-assisted therapy siphoning demand (under-the-radar)
    • 4.3.4 Value-based pricing & parity laws squeezing margins (under-the-radar)
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter’s Five Forces
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Suppliers
    • 4.7.3 Bargaining Power of Buyers
    • 4.7.4 Threat of Substitute Products
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts

  • 5.1 By Drug Class (Value)
    • 5.1.1 Selective Serotonin Reuptake Inhibitors (SSRIs)
    • 5.1.2 Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)
    • 5.1.3 Tricyclic Antidepressants (TCAs)
    • 5.1.4 Monoamine Oxidase Inhibitors (MAOIs)
    • 5.1.5 Atypical Antipsychotics
    • 5.1.6 Benzodiazepines
    • 5.1.7 Others
  • 5.2 By Indication (Value)
    • 5.2.1 Major Depressive Disorder
    • 5.2.2 Generalized Anxiety Disorder
    • 5.2.3 Panic Disorder
    • 5.2.4 Social Anxiety Disorder
    • 5.2.5 Obsessive-Compulsive Disorder
    • 5.2.6 Others
  • 5.3 By Therapy Type (Value)
    • 5.3.1 Pharmacotherapy
    • 5.3.2 Psychotherapy (e.g., CBT)
    • 5.3.3 Neuromodulation & Device-based Therapies
    • 5.3.4 Digital Therapeutics
  • 5.4 By End User (Value)
    • 5.4.1 Hospitals & Clinics
    • 5.4.2 Specialty Mental-Health Centers
    • 5.4.3 Homecare Settings
    • 5.4.4 Others
  • 5.5 By Geography (Value)
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 South America
    • 5.5.2.1 Brazil
    • 5.5.2.2 Argentina
    • 5.5.2.3 Rest of South America
    • 5.5.3 Europe
    • 5.5.3.1 Germany
    • 5.5.3.2 United Kingdom
    • 5.5.3.3 France
    • 5.5.3.4 Italy
    • 5.5.3.5 Spain
    • 5.5.3.6 Rest of Europe
    • 5.5.4 Asia-Pacific
    • 5.5.4.1 China
    • 5.5.4.2 Japan
    • 5.5.4.3 India
    • 5.5.4.4 South Korea
    • 5.5.4.5 Australia
    • 5.5.4.6 Rest of Asia-Pacific
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America
    • 5.5.6 Middle East and Africa
    • 5.5.6.1 GCC
    • 5.5.6.2 South Africa
    • 5.5.6.3 Rest of Middle East and Africa

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Eli Lilly and Company
    • 6.3.2 Pfizer Inc.
    • 6.3.3 GlaxoSmithKline plc
    • 6.3.4 Johnson & Johnson (Janssen)
    • 6.3.5 AstraZeneca plc
    • 6.3.6 Lundbeck A/S
    • 6.3.7 AbbVie (Allergan)
    • 6.3.8 Takeda Pharmaceutical Co.
    • 6.3.9 Otsuka Pharmaceutical Co.
    • 6.3.10 Bausch Health Companies Inc.
    • 6.3.11 Teva Pharmaceutical Industries Ltd.
    • 6.3.12 Sun Pharma Industries Ltd.
    • 6.3.13 Novartis AG
    • 6.3.14 Merck & Co., Inc.
    • 6.3.15 Boehringer Ingelheim GmbH
    • 6.3.16 Alkermes plc
    • 6.3.17 Sage Therapeutics Inc.
    • 6.3.18 Biogen Inc.
    • 6.3.19 MindMed Inc.
    • 6.3.20 Compass Pathways plc

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Anxiety Disorders And Depression Treatment Market Report Scope

As per the scope, depression and some anxiety disorders can be treated with antidepressant drugs and therapy. The market includes both devices and therapy in the scope. The Anxiety Disorders and Depression Treatment Market is Segmented by Product (Antidepressant Drugs, Therapy and Devices, and Others), Indication (Obsessive-Compulsive Disorder, Major Depressive Disorder, Phobia, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD million) for the above segments.

By Drug Class (Value) Selective Serotonin Reuptake Inhibitors (SSRIs)
Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)
Tricyclic Antidepressants (TCAs)
Monoamine Oxidase Inhibitors (MAOIs)
Atypical Antipsychotics
Benzodiazepines
Others
By Indication (Value) Major Depressive Disorder
Generalized Anxiety Disorder
Panic Disorder
Social Anxiety Disorder
Obsessive-Compulsive Disorder
Others
By Therapy Type (Value) Pharmacotherapy
Psychotherapy (e.g., CBT)
Neuromodulation & Device-based Therapies
Digital Therapeutics
By End User (Value) Hospitals & Clinics
Specialty Mental-Health Centers
Homecare Settings
Others
By Geography (Value) North America United States
Canada
Mexico
South America Brazil
Argentina
Rest of South America
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Brazil
Argentina
Rest of South America
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
By Drug Class (Value)
Selective Serotonin Reuptake Inhibitors (SSRIs)
Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)
Tricyclic Antidepressants (TCAs)
Monoamine Oxidase Inhibitors (MAOIs)
Atypical Antipsychotics
Benzodiazepines
Others
By Indication (Value)
Major Depressive Disorder
Generalized Anxiety Disorder
Panic Disorder
Social Anxiety Disorder
Obsessive-Compulsive Disorder
Others
By Therapy Type (Value)
Pharmacotherapy
Psychotherapy (e.g., CBT)
Neuromodulation & Device-based Therapies
Digital Therapeutics
By End User (Value)
Hospitals & Clinics
Specialty Mental-Health Centers
Homecare Settings
Others
By Geography (Value)
North America United States
Canada
Mexico
South America Brazil
Argentina
Rest of South America
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Brazil
Argentina
Rest of South America
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the Anxiety disorder and depression treatment market?

It reached USD 22.65 billion in 2025 and is projected to climb to USD 29.36 billion by 2030 at a 5.32% CAGR.

Which drug class generates the highest revenue?

SSRIs lead with 41.45% revenue in 2024, although atypical antipsychotics are the fastest-growing segment at 6.92% CAGR.

Why are digital therapeutics important for this market?

FDA clearance of Rejoyn validates software-based adjuncts that improve adherence and outcomes, fueling a 6.35% CAGR for digital solutions.

Which is the fastest growing region in Global Anxiety Disorders and Depression Treatment Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region will grow fastest?

Asia-Pacific is expected to expand at an 8.02% CAGR due to regulatory modernization, stigma reduction, and rising healthcare access.

How are parity laws affecting manufacturers?

U.S. parity requirements shift reimbursement to value-based contracts, pressuring margins unless firms provide real-world outcome data.

Global Anxiety Disorders And Depression Treatment Market Report Snapshots